Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
© Oertel et al; licensee BioMed Central Ltd. 2011
Received: 28 April 2011
Accepted: 20 September 2011
Published: 20 September 2011
The pan-HDAC inhibitor (HDACI) suberoylanilide hydroxamic acid (SAHA) has previously shown to be a radio-sensitizer to conventional photon radiotherapy (XRT) in pediatric sarcoma cell lines. Here, we investigate its effect on the response of two sarcoma cell lines and a normal tissue cell line to heavy ion irradiation (HIT).
Materials and methods
Clonogenic assays after different doses of heavy ions were performed. DNA damage and repair were evaluated by measuring γH2AX via flow-cytometry. Apoptosis and cell cycle analysis were also measured via flow cytometry. Protein expression of repair proteins, p53 and p21 were measured using immunoblot analysis. Changes of nuclear architecture after treatment with SAHA and HIT were observed in one of the sarcoma cell lines via light microscopy after staining towards chromatin and γH2AX.
Corresponding with previously reported photon data, SAHA lead to an increase of sensitivity to heavy ions along with an increase of DSB and apoptosis in the two sarcoma cell lines. In contrast, in the osteoblast cell line (hFOB 1.19), the combination of SAHA and HIT showed a significant radio-protective effect. Laser scanning microscopy revealed no significant morphologic changes after HIT compared to the combined treatment with SAHA. Immunoblot analysis revealed no significant up or down regulation of p53. However, p21 was significantly increased by SAHA and combination treatment as compared to HIT only in the two sarcoma cell lines - again in contrast to the osteoblast cell line. Changes in the repair kinetics of DSB p53-independent apoptosis with p21 involvement may be part of the underlying mechanisms for radio-sensitization by SAHA.
Our in vitro data suggest an increase of the therapeutic ratio by the combination of SAHA with HIT in infantile sarcoma cell lines.
KeywordsInfantile sarcoma histone deacetylase inhibition heavy ion radiotherapy suberoylanilide hydroxamic acid SAHA
HDAC inhibitors (HDACI) induce growth arrest and affect cell differentiation, apoptosis and anti-angiogenic effects in tumor cells by chromatin modification with both transcription-dependent and independent mechanisms implicated [1, 2].
Suberoylanilide hydroxamic acid (SAHA) is the first HDACI that has been approved in the United States by the Food and Drug Administration (FDA) for the treatment of relapsed and refractory cutaneous T-cell lymphoma. It has also shown promising preclinical results in vitro and in vivo for several other cancer types [3–5]. Interesting selective synergistic effects by combination of SAHA with other cytotoxic agents, amongst others radiation, have been reported for osteosarcoma cells [6, 7] as well as for many other types of cancer cells [8–10].
In a previous report, we have shown that SAHA enhances radio-sensitivity to conventional megavoltage photon beam radiation (XRT) in multiple pediatric sarcoma cell lines .
DNA double-strand breaks (DSBs) arise from exposure to ionizing radiation. Cells have evolved mechanisms to repair these lesions that are otherwise lethal. These mechanisms involve phosphorylation of histone H2AX (then called γH2AX) and the loading of repair proteins on the chromatin adjacent to the DSBs. It has also been shown that the chromatin architecture in the region surrounding the DSB has a critical impact on the ability of cells to mount an effective DNA damage response .
As SAHA is known to modify chromatin structure, we investigated the changes in γH2AX-expression after irradiation and were able to find a correlation of increased radiosensitivity with increased γH2AX-expression as well as prolongation of radiation-induced γH2AX-expression in the sarcoma cell lines, but interestingly not in normal tissue cell lines when SAHA was combined with XRT [C. Blattmann, submitted]. As DSBs are known to occur with a higher frequency in response to heavy ions compared to photon irradiation  we now were interested in the combination of heavy ion radiation with HDACIs.
Heavy ion therapy (HIT) with carbon ions has achieved superior cancer control in tumors with otherwise low radiosensitivity, like sarcomas . Several evident as well as potential advantages over XRT have lead to a wider popularization of HIT with a number of new facilities that have become operational worldwide. First in vitro data show promising effects by the combination of HIT and SAHA in esophageal cancer cells .
Here we investigate the effect of the HDACI SAHA in combination with HIT on two pediatric sarcoma cell lines (KHOS24-OS (osteosarcoma), A-204 (rhabdomyosarcoma)), as well as a normal tissue cell line (HFOB1.19, human osteoblast).
Materials and methods
Human sarcoma cell lines (KHOS24-OS and A-204), as well as the human osteoblast hFOB 1.19 were obtained from the American Type Culture Collection (ATCC; Rockville, MD).
SAHA was obtained from Alexis Biochemicals (Lörrach, Germany). Primary monoclonal mouse antibodies against Rad51, Ku70 and Ku80, p21 and p53 were obtained from Abcam (Cambridge, UK). Primary monoclonal mouse antibodies against ß-actin as well as a secondary antibody for immunoblot experiments were purchased from CellSignaling Technology (Danvers, MA, USA). For the flow cytometry experiments as well as immunoblots, γH2AX antibody Alexa Fluor® 488 anti-H2A.X-phosphorylated (Ser139) was obtained from BioLegend (San Diego, USA).
Clonogenic assays were performed as described previously . In brief, exponentially growing tumor cells were plated in T25 culture bottles at appropriate numbers to give an estimated 50-250 colonies/flask and were incubated with medium containing 0 to 5 μM SAHA. Incubation of SAHA with the respective LD20 and LD50 for each cell line started 24 h before XRT/HIT. Incubation was stopped after 5 days. Monolayers were stained with 0.5% crystal violet for 10 minutes. Plates were stained with 0.1 M sodium citrate (pH 4) in ethanol 100% (3:1) for another 10 minutes. Afterwards, plates were dried for 48 to 72 h and colonies were counted manually. Survival was defined as the ability of cells to form colonies (≥ 50 cells).
Surviving fractions were obtained by normalizing the plating efficiencies (cell number/plated cell) to the respective control values. Each experiment was done in triplicate and at least three independent repetitions were performed. In combination experiments, the survival rates after different doses of radiation were normalized to the treatment with SAHA given alone.
Following a theoretical concept of combination effects by Steel and Peckham [15, 16] the range of additivity was calculated from the response to the LD 20 of the single agent. This range is encompassed by the prediction of independent cell killing (accounted for by normalizing the radiation survival rates to SAHA toxicity, see above) and a theoretical survival curve that can be obtained if the fraction of cells surviving drug treatment is formally treated as being irradiated with an isoeffective dose D¢. Assuming that the radiation sensitivity coefficients were ax and bx, one readily finds that the theoretical survival curve (normalized to drug toxicity) can be written as SF = exp(- a p D- bxD 2) with a p = ax + 2bxD¢. For graphical representation of the combination effect in excess of independent cell killing, both the experimental survival fraction (cell number/plated cells) and the fitted survival curves were multiplied with the averaged surviving fraction after SAHA exposure alone.
Flow cytometric analysis of γH2AX-expression, cell cycle and apoptosis
Cells were seeded in T25 culture plates at a density of 1 × 106 cells per plate 24 h before HIT. In the SAHA experiments, 0.5-1 μM SAHA was added 24 h before HIT. At certain time points after HIT, cells were harvested and centrifuged (800 g). Cells were washed with PBS several times and then fixed with 3% paraformaldehyde (PFA, Sigma) for 10 min at room temperature (RT). Ice-cold methanol (90%) was added and samples were kept on ice for another 30 min. Afterwards, samples were washed three times in 0.5% BSA/PBS re-suspended in 100 μl 0.5% BSA/PBS and incubated for 10 min at room temperature. Cells were stained for γH2AX by 1 h incubation at RT in 10 μl antibody plus 90 μl 0.5% BSA/PBS per sample. Finally, cells were washed three times with 0.5% BSA/PBS. Cells were further stained with DAPI for cell cycle analysis for 30 min at RT and analyzed simultaneously with the γH2AX staining. The samples were analyzed directly on a "Galaxy Pro"- Flowcytometer from Partec (Münster, Germany). The relative fluorescence intensity in the gated areas was calculated using the multiparameter "Flow max" software from Partec as described in a further report. For the detection of apoptotic cells we used Nicoletti stain measured in a FACS Calibur Flow cytometer (Becton Dickinson Cytometry Systems, San Jose, CA) as described in our earlier report .
To assess the mean extent of DNA damage at a particular phase of the cell cycle, the mean values of γH2AX immunfluorescence were calculated separately for G0/1, S and G2/M cells by the computer-interactive "gating" analysis. Cells in S and G2/M have 1.5 and 2.0 times higher γH2AX mean immunofluorescence respectively, compared to cells in G0/1 because of the increase of DNA and histone content during the cell cycle. Therefore, the data has to be normalized for DNA (histone) content by dividing the mean γH2AX immunofluorescence of S- and G2/M-phase cells by 1.5 and 2.0, respectively. Finally, a low level of γH2AX immunofluorescence is seen in the untreated cells which represent an "intrinsic" γH2AX phosphorylation. Therefore, the γH2AX immunofluorescence level of the untreated controls has to be subtracted from the immunofluorescence level of the treated cells in order to get the γH2AX immunofluorescence level which is treatment-related. Then multiparametric analysis was done on a Galaxy pro flow cytometer (PARTEC, Münster, Germany) by stimulating the fluorochromes DAPI with mercury 100 W vapour lamp, H2AX-FITC with a 488 nm air cooled argon laser and measuring the fluorescence intensities at 530/30 nm and apoptotic cells stained with Nicoletti stain/DAPI/propidium iodide (PI) at 610/20 nm. The green fluorescent FITC, and red fluorescent PI, was measured in the logarithmic mode, DAPI stained DNA measured in linear mode. Analysis and calculation the Flow Max software (Partec, Münster, Germany was used. Each analysis represents 5000 cells.
Immunoblot analysis was performed as reported previously . In brief, following treatment, cells were lysed with lysis buffer (0.5 M tris/Cl, pH 6,8, SDS, 87% Glycerin, DTT 1 M ad Aqua 100 ml). Following this, 1 ml lysate was incubated with 1 μl benzonase for 15 min at 37°C. 40 μg of protein extracts underwent electrophoresis onto a 12% polyacrylamide gel (Pierce Biotechnology Inc., Roxford, IL, USA) under reducing conditions. The separated proteins were transferred onto nitrocellulose membranes (Amersham Pharmacia Bioscience, Piscataway, NJ). The membranes were then incubated for 45 minutes in blocking buffer (tris-buffered saline with 0.1% Tween (TBS-T) and 5% nonfat dry milk), followed by incubation with specific primary antibodies at 1:1000 dilution at -4°C for 24 h or at room temperature for 1 h. After being washed with TBS-T buffer three times, the membrane was incubated with anti-mouse IgG secondary antibody (Cell Signaling Technology, Danvers, MA, USA) at 1:1000 dilution for 1 h at room temperature. The signals were visualized with the ECL+ detection system and autoradiography.
Confocal Laser Scanning Microscopy
The nuclear organization of chromatin and γHSAX in KHOS-24 OS cells upon treatment with SAHA, HIT and both in combination was observed by laser scanning microscopy using a Zeiss LSM 700, equipped with a 63 × oil objective. Images were acquired with pinhole-size 1 Airy at pixel-size 100 nm. Cells were fixed with buffered 2% formaldehyde, chromatin stained with DAPI and γH2AX revealed by IHC using Alexa 488-charged secondary antibody as reporter.
All experiments were performed at least twice. Furthermore, each experiment was done in duplicate. Clonogenic assays were performed in triplicate. Combination studies were evaluated using student's t test with the resulting p value representing a two-sided test of statistical significance.
HDACI have been reported to prevent radiation-induced toxicity on normal tissue after XRT , while sensitizing tumor cells [7, 20, 21]. We are the first to show a promising, even selective effect by the combination of HIT and HDACI in infantile sarcoma cells.
We have previously reported on the ability of the HDACI SAHA to selectively radio-sensitize pediatric sarcoma cell lines to photon treatment as opposed to normal tissue cell lines  suggesting a therapeutic benefit by this combination. HIT is a further promising alternative to XRT in otherwise often radio-resistant sarcomas due to the superb biological effectiveness and dose conformity. However, the potential of heavy ions to cause adverse late effects such as secondary cancer must not be overlooked, especially in young and pediatric patients. Clinical studies are underway . Despite the favorable clinical outcome of HIT alone, the interest in combination treatments, especially substances that ameliorate heavy ion-induced damage to normal cells, is increasing. Therefore the combination of HIT with molecularly targeted approaches like the combination with HDACI is worth investigating.
Apoptosis, necrosis, autophagy and delayed reproductive death of progeny cells are possible mechanisms for cell death after HIT. Further possible effects of HIT are cell inactivation by premature senescence as well as accelerated differentiation. Previous studies have shown that changes in chromatin organization, as induced by HDACI, modify cell morphology and de-condensate chromatin, which seems to interrelate with cellular radio-sensitivity . Changes in cellular ultrastructure and increased autophagic vacuoles have been observed after heavy-ion exposure . In consequence of these reports, we hoped to find further hints towards the underlying mechanism of HDACI-induced changes in sensitivity to HIT by microscopy. We observed KHOS-24OS after SAHA alone, combination treatment with HIT and SAHA and HIT only. However, no trend-setting differences in cell morphology were observable.
In contrast to our previous findings concerning the combination of XRT and SAHA in the three cell lines investigated , repair protein expression was not influenced by the combination of SAHA and HIT in A-204, but only in KHOS-24OS. It has previously been reported that high-LET radiation induces different changes in gene expression as compared to low-LET XRT a possible explanation for this discrepancy ; However, the combination of SAHA with either XRT or HIT showed similar effects on the repair kinetics of DSB as measured by γH2AX, despite the different reaction on the protein expression level immediately after treatment.
The fact that HDACI enhance radio-response to XRT of human tumor cells by impairing the repair of DNA damage has been reported earlier [22, 23]. Our data show that this is also true for our infantile sarcoma cell lines and the combination with HIT. As shown by Hamada et al., γH2AX focus disappearance, i.e. DNA-repair, proved to be significantly slower after treatment with high-LET HIT than with XRT in both sarcoma cell lines, as well as the osteoblast cell line . SAHA increased this effect in the sarcoma cell lines, but showed a protective effect on the osteoblast cell line. The significantly decreased number of DSB in the osteoblast cell lines after combination treatment with SAHA and HIT compared to HIT only substantiates the hope that SAHA increases the therapeutic ratio. This is consistent with our earlier results, as well as many other reports that showed the ability of HDACI to prevent radiation-induced toxicity on normal tissue after XRT [7, 17],
We deliberately chose two infantile sarcoma cell lines with differing properties for our experiments. KHOS-24OS is a tetraploid osteosarcoma cell line with a known p53 mutation, A-204 a diploid and tetraploid rhabdomyosarcoma cell line with wild-type p53.
KHOS-24OS showed a lower sensitivity to XRT radiation compared to A-204 , which is in line to the mutated p53. Multiple pathways are involved in maintaining the genetic integrity of a cell after exposure to ionizing radiation. A common cellular response to DNA damaging agents is the activation of cell cycle checkpoints. One of the key proteins in the checkpoint pathways is the tumor suppressor gene p53, which is frequently damaged in tumor cells and mediates the two major DNA damage-dependent cellular checkpoints at the G(1)-S transition and at the G(2)-M transition . p53 mutations often lead to XRT resistance . While KHOS-24OS contains mutated p53, A-204 is a p53-wild type cell line . High-LET irradiation treatment with heavy ions has previously been shown to be less dependent on the cellular p53 status, resulting in a lower radiobiological effectiveness (RBE) in those cells that are more sensitive to photon treatment due to p53-dependent apoptosis . HDAC inhibitors are also known to enhance mechanisms leading to apoptosis independently from the p53 status .
The p53 mutation may explain why HIT compared to XRT has a stronger effect in KHOS-24OS than in A-204 cells. However, HIT and SAHA are promising in A-204 as well, and the synergistic effect of HIT and SAHA was altogether only a little more pronounced in the p53 mutated cell line KHOS-24OS. Radio-sensitization to HIT by SAHA thus seems to be independent of p53, as previously described for either single agent alone . While p53 expression was not affected by SAHA, HIT or the combination, p21 was up-regulated in the sarcoma cell lines by SAHA as well as SAHA+HIT and down-regulated in the osteoblast cell line, correlating well to the observed apoptotic reactions of the sarcoma cell lines in contrast to hFOB1.19. p21 is known to influence cell proliferation, regulation of S-phase DNA-replication, as well as DNA-repair. The observed therapy-related changes in cell cycle progression may be induced by p21 interaction. However, in contrast to XRT, heavy ion irradiation is known to be effective at killing cells with little cell-cycle dependency . While p21 does not by itself induce apoptosis, it does interact with caspase-associated, p53-independent apoptotic pathways .
Interestingly, however, the influence of the combination therapy of SAHA with HIT, as well as XRT on the repair kinetics as represented by the γH2AX-response, proved to be higher in A-204 than in KHOS-24OS (Figure 5). Here p53 may play a role after all. It has previously been reported, that p53 wild-type cancer cells show a faster loss of γH2AX after XRT than cells with p53 deficiency . Our findings suggest that this is also true for HIT, especially when combined with SAHA. As suggested by Hamada et al., high-LET radiation may be particularly effective in patients with mutated p53 or p53 depleted tumors and the addition of a HDACI may be of additional value . p21 has been demonstrated to be a predictive marker for response to HDACI treatment alone in sarcomas . Our findings warrant further investigations whether p21 status of sarcomas may serve as an additional prognostic marker for the efficacy of combined HIT with HDACI.
Our study shows that SAHA is an intriguing novel adjuvant to HIT in certain sarcomas.
The combination of HDACI like SAHA with HIT may be a promising strategy in the treatment of infantile sarcomas. Our data suggest an improvement of therapeutic ratio.
List of abbreviations used
DNA double-strand breaks
Heavy ion therapy
Suberoylanilide hydroxamic acid.
We would like to thank Sylvia Trinh, Ludmilla Frick and Gabriele Becker for their excellent technical work. This work was supported by the Dietmar Hopp Stiftung, Germany.
- Minucci S, Pelicci P: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6: 38-51. 10.1038/nrc1779View ArticlePubMedGoogle Scholar
- Wilson AJ, Chueh AC, Tögel L, et al.: Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 2010,70(2):609-620. 10.1158/0008-5472.CAN-09-2327PubMed CentralView ArticlePubMedGoogle Scholar
- Furchert SE, Lanvers-Kaminsky C, Jürgens H, et al.: Inhibitor of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007, 120: 1787-1794. 10.1002/ijc.22401View ArticlePubMedGoogle Scholar
- Lee M-J, Kim YS, Kummar S, et al.: Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 2008, 20: 639-649. 10.1097/CCO.0b013e3283127095View ArticlePubMedGoogle Scholar
- Dalgard CL, Van Quil KR, O'Brien JM, et al.: Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 2008,14(10):3113-3123. 10.1158/1078-0432.CCR-07-4836View ArticlePubMedGoogle Scholar
- Yang C, Choy E, Hornicek FJ, et al.: Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 2011,67(2):439-46. 10.1007/s00280-010-1344-7View ArticlePubMedGoogle Scholar
- Blattmann C, Oertel S, Ehemann V, et al.: Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2010,78(1):237-245. 10.1016/j.ijrobp.2010.03.010View ArticlePubMedGoogle Scholar
- Camphausen K, Tofilon PJ: Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007, 25: 4051-4056. 10.1200/JCO.2007.11.6202View ArticlePubMedGoogle Scholar
- Karagiannis TC, El Osta A: Modulation of cellular radiation response by histone deacetylase inhibitors. Oncogene 2006, 25: 3885-3893. 10.1038/sj.onc.1209417View ArticlePubMedGoogle Scholar
- Munshi A, Tanaka T, Hobbs ML, et al.: Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006, 5: 1967-74. 10.1158/1535-7163.MCT-06-0022View ArticlePubMedGoogle Scholar
- Xu Y, Price BD: Chromatin dynamics and the repair of DANN double strand breaks. Cell Cycle 2011,10(2):261-267. 10.4161/cc.10.2.14543PubMed CentralView ArticlePubMedGoogle Scholar
- Hada M, Sutherland BM: Spectrum of complex DNA damages depends on the incident radiation. Radiat Res 2006,165(2):223-30. 10.1667/RR3498.1View ArticlePubMedGoogle Scholar
- Blattmann C, Oertel S, Schulz-Ertner D, et al.: Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer 2010, 10: 96. 10.1186/1471-2407-10-96PubMed CentralView ArticlePubMedGoogle Scholar
- Kano M, Yamada S, Hoshino I, et al.: Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res 2009,29(11):4433-8.PubMedGoogle Scholar
- Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979, 5: 85-91.View ArticlePubMedGoogle Scholar
- O'Connor OA, Heaney ML, Schwartz L, et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24: 166-73. 10.1200/JCO.2005.01.9679View ArticlePubMedGoogle Scholar
- Baschnagel A, Russo A, Burgan WE, et al.: Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009,8(6):1589-95. 10.1158/1535-7163.MCT-09-0038PubMed CentralView ArticlePubMedGoogle Scholar
- Vasirredy RS, Shung CN, Cempaka NL, et al.: H2AX phosphorylation screens from radiosensitive cancer patients reveals a novel DNA double-strand break repair cellular phenotype. Br J Cancer 2010,102(10):1511-1518. 10.1038/sj.bjc.6605666View ArticleGoogle Scholar
- Chung YL, Lee MY, Pui NN: Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 2009,30(8):1387-1397. 10.1093/carcin/bgp079View ArticlePubMedGoogle Scholar
- Chinnaiyan P, Vallabhaneni G, Armstrong E, et al.: Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005, 62: 223-9. 10.1016/j.ijrobp.2004.12.088View ArticlePubMedGoogle Scholar
- Camphausen K, Burgan W, Cerra M, et al.: Enhanced radiation-induced cell killing and prolongation of χH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004, 64: 316-21. 10.1158/0008-5472.CAN-03-2630View ArticlePubMedGoogle Scholar
- Storch K, Eke I, Borgmann K, et al.: Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 2010, 70: 3925-34. 10.1158/0008-5472.CAN-09-3848View ArticlePubMedGoogle Scholar
- Oishi T, et al.: Proliferation and cell death of human glioblastoma cells after carbon-ion beam exposure: morphologic and morphometric analyses. Neuropathology 2008, 28: 408-416. 10.1111/j.1440-1789.2008.00899.xView ArticlePubMedGoogle Scholar
- Hamada N, Tatsuhiko I, Masunaga S, et al.: Recent advances in the Biology of heavy-ion cancer therapy. J Radiat Res 2010, 51: 365-83. 10.1269/jrr.09137View ArticlePubMedGoogle Scholar
- Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004,59(4):928-42. 10.1016/j.ijrobp.2004.03.005View ArticlePubMedGoogle Scholar
- Hollstein M, et al.: p53 mutations in human cancers. Science 2001, 253: 49-53.View ArticleGoogle Scholar
- Diller , Kassel J, Nelson CE, et al.: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990,10(11):5772-5781.PubMed CentralView ArticlePubMedGoogle Scholar
- Takahashi T, Fukawa T, Hirayama R, et al.: In vitro interaction of high-LET heavy-ion irradiation and chemotherapeutic agents in two cell lines with different radiosensitivities and different p53 status. Anticancer Res 2010,30(6):1961-7.PubMedGoogle Scholar
- Singh TR, Shankar S, Srivastava RK: HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005, 24: 4609-23. 10.1038/sj.onc.1208585View ArticlePubMedGoogle Scholar
- Takahashi A, Matsumoto H, Furusawa Y, et al.: Apoptosis induced by high-LET radiations is not affected by cellular p53 gene status. Int J Radiat Biol 2005, 81: 581-6. 10.1080/09553000500280484View ArticlePubMedGoogle Scholar
- Blakely EA, Chang PY: Biology of charged particles. Cancer J 2009, 15: 271-84. 10.1097/PPO.0b013e3181b666c5View ArticlePubMedGoogle Scholar
- Huo JX, Metz SA, Li GD: p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ 2004,11(1):99-109. 10.1038/sj.cdd.4401322View ArticlePubMedGoogle Scholar
- Banath J, MacPhail S, Olive P: Radiation Sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell cines. Cancer Res 2004, 64: 7144-9. 10.1158/0008-5472.CAN-04-1433View ArticlePubMedGoogle Scholar
- Mills J, Hricik T, Siddiqi S, et al.: Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Mol Cancer Ther 2011, (10):313-323.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.